BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JS212 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JS212\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07484724-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JS212: Phase 2 readout est. (NCT07484724)
DESCRIPTION:JS212\, phase 2.\nStudy: A Study Evaluating the Safety and Effi
 cacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squ
 amous Cell Carcinoma\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/js212#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07484724
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309276-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:JS212: Phase 2 readout est. (NCT07309276)
DESCRIPTION:JS212\, phase 2.\nStudy: A Phase II Clinical Study Evaluating t
 he Combination Therapy of JS212 in Patients With Advanced Lung Cancer\nEst
 imated primary completion: 30 November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/js212#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07309276
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480733-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:JS212: Phase 2 readout est. (NCT07480733)
DESCRIPTION:JS212\, phase 2.\nStudy: Phase II Study of JS212/JS213 as Monot
 herapy and in Combination in Patients With Advanced Malignant Solid Tumors
 \nEstimated primary completion: 30 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/js212#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07480733
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:JS212: Phase 2 readout est. (NCT07503756)
DESCRIPTION:JS212\, phase 2.\nStudy: JS212 Combination Therapies in Metasta
 tic Colorectal Cancer\nEstimated primary completion: 30 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/js212#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07503756
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888830-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS212: Phase 1/2 readout est. (NCT06888830)
DESCRIPTION:JS212\, phase 1/2.\nStudy: A Phase I/II Clinical Study to Evalu
 ate the Safety\, Tolerability\, Pharmacokinetics and Initial Efficacy of J
 S212 in Subjects With Advanced Malignant Solid Tumour\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/js212#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06888830
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876557-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS212: Phase 2 readout est. (NCT07876557)
DESCRIPTION:JS212\, phase 2.\nStudy: A Clinical Study to Evaluate the Effic
 acy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or
  Metastatic Triple-negative Breast Cancer(TNBC)\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/js212#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07876557
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518160-2571@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:JS212: Phase 2 readout est. (NCT07518160)
DESCRIPTION:JS212\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS212 Plu
 s JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study\nEstimated primary
  completion: 23 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/js212#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07518160
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
